Home » Stocks » NTGN

Neon Therapeutics, Inc. (NTGN)

May 6, 2020 - NTGN was delisted (reason: acquired by BNTX)
Stock Price: $3.07 USD 0.00 (0.00%)
Updated May 6, 2020 4:00 PM EDT
Market Cap 88.93M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 28.96M
EPS (ttm) -2.68
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 6, 2020
Last Price $3.07
Previous Close $3.07
Change ($) 0.00
Change (%) 0.00%
Day's Open -
Day's Range 2.92 - 3.09
Day's Volume 3,609,767
52-Week Range 0.88 - 6.15

News

Hide News
GlobeNewsWire - 8 months ago

Phase 1 Clinical Trial of Personal Neoantigen-Targeted T Cell Therapy Expected to Initiate in Third Quarter 2020 Phase 1 Clinical Trial of Personal Neoantigen-Targeted T Cell Therapy Expected ...

Seeking Alpha - 11 months ago

BioNTech's Acquisition Of Neon Highlights Potential Use Of Neoantigens For Cancer Treatment

Other stocks mentioned: BNTX
24/7 Wall Street - 11 months ago

As the biotechnology group is pushing near all-time highs, this past week played host to a huge number of biotech movers.

Other stocks mentioned: ADAP, AQST, BNTX, DARE, NKTR
InvestorPlace - 11 months ago

Neon Therapeutics (NTGN ) news for Thursday about a $67.00 million deal with BioNTech (BNTX) has NTGN stock soaring on Thursday. The post Neon Therapeutics News: NTGN Stock Rockets 38% on BioN...

24/7 Wall Street - 11 months ago

Neon Therapeutics Inc. (NASDAQ: NTGN) shares shot up on Thursday after the firm announced that it will be acquired by BioNTech SE (NASDAQ: BNTX).

GlobeNewsWire - 11 months ago

MAINZ, Germany and CAMBRIDGE, Mass., Jan. 16, 2020 (GLOBE NEWSWIRE) -- BioNTech (Nasdaq: BNTX, “BioNTech”) and Neon Therapeutics, Inc. (Nasdaq: NTGN, “Neon”) today announced that they have e...

GlobeNewsWire - 1 year ago

Study of NEO-PTC-01 in metastatic melanoma patients expected to initiate in first half of 2020 Study of NEO-PTC-01 in metastatic melanoma patients expected to initiate in first half of 2020

Market Watch - 1 year ago

Shares of Neon Therapeutics NTGN, -4.03% were up 19% in after-hours trading Wednesday after the company announced a corporate restructuring that includes cutting 24% of its workforce.

GlobeNewsWire - 1 year ago

Lead program, NEO-PTC-01, is a personalized neoantigen adoptive T cell therapy candidate to address refractory solid tumors

GlobeNewsWire - 1 year ago

Updated Results from NT-001 Trial of NEO-PV-01 Demonstrate Prolonged Progression-Free and Overall Survival vs. Historical Benchmark Data

GlobeNewsWire - 1 year ago

Proprietary class II prediction tool achieved up to a 61-fold improvement in predicting MHC class II peptides compared to standard methods

Seeking Alpha - 1 year ago

Neon Therapeutics achieved positive results using NEO-PV-01 when combined with OPDIVO in patients with a few types of cancer.

Benzinga - 1 year ago

Neon Therapeutics (NASDAQ: NTGN) shares are trading higher after the company announced its personal neoantigen vaccine study demonstrated prolonged progression-free survival in advanced or met...

About NTGN

Neon Therapeutics, a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial for the treatment of advanced or metastatic non-small cell lung cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of hormone-receptor-positive breast cancer, as well as NEO-STC-01, a neoantigen adoptive T cell therapy for the treatm... [Read more...]

Industry
Biotechnology
IPO Date
Jun 27, 2018
Stock Exchange
NASDAQ
Ticker Symbol
NTGN
Full Company Profile

Financial Performance

Financial Statements